Thesis(M.A.)--Auburn University, 2006. / Abstract. Vita. Includes bibliographic references.

Thesis (Psy. D.)--Indiana University of Pennsylvania. / Includes bibliographical references.

Thesis (DPsych (Counselling Psychology)) - Swinburne University of Technology, 2007. / Submitted as partial requirement for Doctorate of Psychology (Counselling), Swinburne University of Technology - 2007. Typescript. Includes bibliographical references (p. 194-225).

Thesis (M.A.)--Georgia State University, 2008. / Title from file title page. James Emshoff, committee chair; Gabriel Kuperminc, Marci Culley, committee members. Electronic text (79 p.) : digital, PDF file. Description based on contents viewed June 9, 2008. Includes bibliographical references (p. 45-68).

Thesis (M.A.)--Eastern Illinois University, 2009. / Includes bibliographical references (leaves 65-72).

No description available.

published_or_final_version / Chinese Medicine / Master / Master of Philosophy

The Substance Abuse Subtle Screening Inventory was constructed to screen for substance abuse patterns despite non-admittance of respondents. Predictive validity studies of the SASSI are limited, and are not available for probationers. Participants were 147 male and 54 female probationers mandated to treatment. Overall differences among SASSI scales were significant for treatment compliance and outcome. Higher SASSI scales were found among those probationers who were compliant/successful. Individual scales were not significantly different, however, a trend was revealed; those respondents who scored higher tended to comply/succeed in treatment. The SASSI alone accurately classified 59.7% of respondents. In summary, the SASSI's use in predicting treatment outcome is limited and should be employed with concomitant data.

A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in partial fulfillment of the requirements for the degree of Master of Medicine in the branch of Psychiatry, Johannesburg, September 2013 / Objective: Anecdotal evidence suggests that substance use is a significant problem among psychiatric patients admitted to Chris Hani Baragwanath Academic Hospital. The purpose of this study was to investigate the prevalence of substance use, the type of substance used and the socio-demographic and clinical factors associated with substance use among a group of psychiatric inpatients. Method: This study was a retrospective record review of all patients admitted to the psychiatric wards at Chris Hani Baragwanath Academic Hospital between the periods of July and December 2008. Results: Substance use was 4.8 (95% CI:2.7-8.4) times more likely among male subjects (p<0.001), 4.1 times (95%CI: 1.8-9.3) more likely in subjects aged 18-30 years compared to older patients (p=0.001), 3 times (95% CI: 1.2-7.4) more likely in subjects who were single (p=0.001), 1.9 (95% CI:1.4-2.7) times more likely in subjects who did not have children (p<0.001), and 1.5 (95% CI:1.2-2.1) times more likely in subjects with a psychotic disorder (p=0.004) compared to those with a mood disorder. Mood and psychotic disorders were compared and only the past psychiatric history was found to be significantly associated with psychotic disorders. Conclusion: Male gender was found to be significantly associated with substance use. Alcohol and cannabis were the most common substances used and polysubstance use also was a common occurrence. These findings have implications for preventative measures, psychiatric practice and specialized care for dual diagnosis patients.

by Tung Wai Lin. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1990. / Bibliography: leaves 110-123. / ACKNOWLEDGEMENT / LIST OF ABBREVIATIONS / ABSTRACT --- p.1 / Chapter CHAPTER 1 --- INTRODUCTION --- p.4 / Chapter 1.1 --- TAURINE IN THE CNS --- p.4 / Chapter 1.1.1 --- General metabolism of taurine --- p.4 / Chapter 1.1.2 --- Release and uptake of taurine by neurons and glia --- p.5 / Chapter 1.1.2.1 --- Taurine uptake --- p.5 / Chapter 1.1.2.2 --- Taurine release --- p.6 / Chapter 1.2 --- FUNCTIONS OF ASTROCYTES --- p.7 / Chapter 1.2.1 --- Potassium homeostasis --- p.8 / Chapter 1.2.2 --- Water homeostasis --- p.9 / Chapter 1.3 --- NEURON-GLIA COMMUNICATION : NEUROTRANSMITTER RECEPTORS AND SECOND MESSENGER SYSTEMS IN ASTROCYTES --- p.11 / Chapter 1.3.1 --- Adenylate cyclase pathway --- p.12 / Chapter 1.3.2 --- Inositol lipid pathway --- p.12 / Chapter 1.3.2.1 --- "Ins(l,4,5)P3/Ca2+ pathway" --- p.13 / Chapter 1.3.2.2 --- DAG/PKC pathway --- p.15 / Chapter 1.3.2.3 --- Dual actions of PKC --- p.16 / Chapter 1.3.3 --- Interaction between second messenger systems --- p.17 / Chapter 1.4 --- SUBSTANCE P RECEPTOR ON ASTROCYTES --- p.18 / Chapter 1.4.1 --- SP and SP receptors --- p.18 / Chapter 1.4.2 --- Evidence for the existence of SP receptor in glial cell --- p.20 / Chapter CHAPTER 2 --- METHODS --- p.23 / Chapter 2.1 --- IN VITRO CULTURE OF HUMAN ASTROCYTOMA CELLS (U-3 7 3 MG) --- p.23 / Chapter 2.1.1 --- Preparation of reagents --- p.23 / Chapter 2.1.2 --- Culture of astrocytoma cells --- p.24 / Chapter 2.1.3 --- Cell plating in 24-well plastic trays --- p.25 / Chapter 2.2 --- DETERMINATION OF [3H]-TAURINE RELEASE --- p.26 / Chapter 2.2.1 --- Physiological salt solution (PSS) --- p.26 / Chapter 2.2.2 --- r> Preparation of working [ H]-taurine solution --- p.26 / Chapter 2.2.3 --- Assay of [ H]-taurine release --- p.26 / Chapter 2.2.4 --- Drug pretreatment --- p.27 / Chapter 2.2.5 --- Data analysis --- p.27 / Chapter 2.3 --- DOWN REGULATION OF PKC ACTIVITY BY PROLONGED PMA PRETREATMENT --- p.29 / Chapter 2.3.1 --- Preparation of working Phorbol-12-myristate-13-acetate (PMA) solution --- p.29 / Chapter 2.3.2 --- Pretreatment of cells with PMA --- p.29 / Chapter 2.4 --- DETERMINATION OF CAMP --- p.29 / Chapter 2.4.1 --- Drugs effects on cAMP --- p.30 / Chapter 2.4.2 --- Data analysis --- p.30 / Chapter 2.5 --- MEASUREMENT OF INOSITOL PHOSPHATES --- p.31 / Chapter 2.5.1 --- Downx column preparation --- p.31 / Chapter 2.5.2 --- Determination of total inositol phosphates accumulation --- p.31 / Chapter 2.5.3 --- Column separation --- p.33 / Chapter 2.5.4 --- Determination of inositol trisphosphate (IP3) --- p.34 / Chapter 2.6 --- MEASUREMENT OF PKC --- p.34 / Chapter 2.6.1 --- Preparation of cytosolic and membrane bound PKC --- p.34 / Chapter 2.6.1.1 --- Reagent preparation --- p.34 / Chapter 2.6.1.2 --- Preparation of DEAE-cellulose column --- p.35 / Chapter 2.6.1.3 --- Protocol of preparing cytosolic and membrane bound PKC --- p.36 / Chapter 2.6.2 --- PKC assay --- p.37 / Chapter 2.6.2.1 --- Reagent preparation --- p.37 / Chapter 2.6.2.2 --- PKC activity assay protocol --- p.38 / Chapter 2.7 --- STATISTICAL METHOD --- p.39 / Chapter CHAPTER 3 --- RESULTS --- p.40 / Chapter 3.1 --- SOME CHARACTERISTICS OF TAURINE TRANSPORT IN U-373 MG ASTROCYTOMA CELLS --- p.40 / Chapter 3.1.1 --- Time and sodium dependence of taurine uptake --- p.40 / Chapter 3.1.2 --- Time dependence of SP-stimulated taurine release --- p.42 / Chapter 3.1.3 --- Effect of ions on SP-stimulated taurine release --- p.42 / Chapter 3.1.3.1 --- Effect of sodium on taurine release --- p.42 / Chapter 3.1.3.2 --- Effect of potassium on taurine release --- p.42 / Chapter 3.1.3.3 --- Effect of calcium and magnesium on taurine release --- p.46 / Chapter 3.1.4 --- Temperature-dependence of [H]-taurine release --- p.49 / Chapter 3.1.5 --- Comparison of chemical-induced release of taurine and GABA from U-373 MG astrocytoma cells --- p.49 / Chapter 3.2 --- PHARMACOLOGICAL STUDIES OF SP-STIMULATED TAURINE RELEASE --- p.49 / Chapter 3.2.1 --- Effect of mammalian tachykinins and their analogues on the release of [3H]-taurine --- p.49 / Chapter 3.2.2 --- Antagonistic effect of spantide on SP-stimulated [3H]-taurine release --- p.51 / Chapter 3.2.3 --- The interaction between SP- and IPR- stimulated taurine release --- p.55 / Chapter 3.2.3.1 --- Concentration dependence of IPR-induced release of [ H]-taurine --- p.55 / Chapter 3.2.3.2 --- Effect of 100 nM IPR on SP-stimulated taurine release --- p.55 / Chapter 3.3 --- SECOND MESSENGER SYSTEMS INVOLVED IN THE REGULATION OF TURINE RELEASE BY SP AND IPR --- p.55 / Chapter 3.3.1 --- The role of cAMP --- p.58 / Chapter 3.3.2 --- The role of phosphatidylinositol bisphosphate (PIP2) metabolism --- p.58 / Chapter 3.3.2.1 --- Time course of SP-induced inositol phosphates accumulation --- p.61 / Chapter 3.3.2.2 --- Pharmacological studies of SP-induced IPs accumulation --- p.61 / Chapter 3.3.2.3 --- Effect of SP on inositol trisphosphate --- p.65 / Chapter 3.3.2.4 --- Effect of IPR on IPs accumulation --- p.65 / Chapter 3.3.3 --- The role of Ca2+ mobilization --- p.65 / Chapter 3.3.4 --- The role of protein kinase C (PKC) --- p.69 / Chapter 3.3.4.1 --- Concentration dependence of PMA-stimulated taurine release --- p.70 / Chapter 3.3.4.2 --- Effect of H7 on the release of taurine --- p.70 / Chapter 3.3.4.3 --- Effect of staurosporine on taurine release --- p.73 / Chapter 3.3.4.4 --- Effect of chronic PMA pretreatment --- p.76 / Chapter 3.3.4.5 --- Measurement of PKC activity --- p.80 / Chapter CHAPTER 4 --- DISCUSSIONS --- p.90 / Chapter 4.1 --- A COMPARISON OF THE CHARACTERISTICS OF TAURINE RELEASE FROM ASTROCYTOMA CELLS AND NEURONS --- p.90 / Chapter 4.2 --- SP-INDUCED [3H]-TAURINE RELEASE FROM U-3 7 3 MG ASTROCYTOMA CELLS --- p.93 / Chapter 4.3 --- THE ROLE OF SECOND MESSENGER SYSTEMS IN THE SP-INDUCED [3H]-TAURINE RELEASE --- p.95 / Chapter 4.4 --- BIOLOGICAL SIGNIFICANCE OF SP-INDUCED TAURINE RELEASE --- p.103 / CONCLUSIONS --- p.107 / REFERENCES --- p.110